Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1864 participants.
Also called NCT02607865
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,864 participants
- Sponsor
- Registry
-
NCT02607865 -
2015-001351-71
-
- Main results
- Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial
- Other papers using this trial's data
- Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Brazil, France, Germany, India, Israel, Japan, Mexico, Romania, Russia, South Africa, Türkiye, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02607865. Randomized; double masking; primary purpose treatment. Start 2016-02-15 (actual); primary completion 2017-02-14 (actual). Results posted on 2020-02-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes
- Acronym
- PIONEER 3
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- semaglutide
- Intervention (Drug)
- sitagliptin
- Intervention (Drug)
- placebo
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct02607865- Content hash
a6ec3fee5c2d28b0b4c0e666e37754ee500e38f9cb3660480885e2514b468878